Cifran

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg;  

Pieejams no:

Douglas Pharmaceuticals Limited

SNN (starptautisko nepatentēto nosaukumu):

Ciprofloxacin hydrochloride 291.79 mg (equivalent to ciprofloxacin 250 mg)

Deva:

250 mg

Zāļu forma:

Film coated tablet

Kompozīcija:

Active: Ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg   Excipient: Colloidal silicon dioxide Magnesium stearate Maize starch Microcrystalline cellulose Opadry white OY-S-58910 Purified talc Purified water   Sodium starch glycolate

Vienības iepakojumā:

Blister pack, PVC/PVDC/aluminium foil, 10, 30 tablets, 10

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Dr Reddy's Laboratories Limited

Produktu pārskats:

Package - Contents - Shelf Life: Blister pack, PVC/PVDC/aluminium foil, 10, 30 tablets - 10 - 36 months from date of manufacture stored at or below 25°C

Autorizācija datums:

2002-04-30

Produkta apraksts

DATA SHEET 

CIFRAN 
CIPROFLOXACIN HYDROCHLORIDE PH. EUR. 250 MG, 500 MG AND 750 MG FILM
COATED TABLETS 

PRESENTATION 

Cifran 250 mg tablets: each tablet contains 291.79 mg ciprofloxacin
hydrochloride, equivalent to 250 
mg ciprofloxacin. Tablets are white to off-white, round, film-coated,
embossed with ‘250’ on one side 
and plain on the other side. 

Cifran 500 mg tablets: each tablet contains 583.59 mg ciprofloxacin
hydrochloride, equivalent to 500 
mg ciprofloxacin. Tablets are white to off-white, caplet-shaped,
film-coated, embossed with ‘500’ on 
one side and plain on the other side. 

Cifran 750 mg tablets: each  tablet contains
875.39 mg ciprofloxacin hydrochloride, equivalent to 750 
mg ciprofloxacin. Tablets are white to off-white, caplet-shaped,
film-coated, embossed with ‘750’ on 
one side and plain on the other side. 

USES 
_ACTIONS _

Ciprofloxacin is a synthetic broad spectrum antibacterial agent
(ATCCODE: J 01 MA 02). 
Ciprofloxacin is effective in vitro against
virtually all gram-negative pathogens, including 
Pseudomonas aeruginosa. It is also effective against gram-positive
pathogen such as staphylococci and 
streptococci. Anaerobes are generally less susceptible. 

Ciprofloxacin has a rapid bactericidal action, both in the
proliferation phase and in the resting phase. 
During the proliferation phase of a bacterium a segmental
twisting and untwisting of the chromosomes 
take place. An enzyme called DNA gyrase plays a decisive part in
this process. Ciprofloxacin inhibits 
this DNA gyrase in a way that arrests the bacterial metabolism,
since vital information can no longer 
be read from the bacterial chromosome. 

Resistance to ciprofloxacin develops slowly and in stages
(multiple-step type). Plasmid-mediated 
resistance development of the kind that occurs
with β-lactam antibiotics, aminoglycosides, and 
tetracyclines has not been observed with ciprofloxacin. It is of
clinical interest t